LncRNAs in necroptosis: Deciphering their role in cancer pathogenesis and therapy DOI
Rahamat Unissa Syed, Selim Afşar,

Nayla Ahmed Mohammed Aboshouk

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 256, С. 155252 - 155252

Опубликована: Март 5, 2024

Язык: Английский

From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression DOI
Riya Thapa, Obaid Afzal, Muhammad Afzal

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 154959 - 154959

Опубликована: Ноя. 19, 2023

Язык: Английский

Процитировано

50

Knockdown of integrin β1 inhibits proliferation and promotes apoptosis in bladder cancer cells DOI

Jin‐feng Wang,

Jianshe Wang, Yang Liu

и другие.

BioFactors, Год журнала: 2024, Номер 51(1)

Опубликована: Дек. 7, 2024

Abstract Bladder cancer (BC) is the most common urinary tract malignancy. Identifying biomarkers that predict prognosis and immune function in patients with BC can enhance our understanding of its pathogenesis provide valuable guidance for diagnosis treatment. Our findings indicate increased ITGB1 expression associated higher clinical grade stage, establishing as an independent prognostic risk factor BC. Enrichment analysis revealed was linked to extracellular matrix. The experimental results showed knockdown cell lines 5637 RT112 reduced their proliferation, migration, invasion. Furthermore, suppression promotes apoptosis cells by inhibiting PI3K‐AKT pathway. A model incorporating CES1, NTNG1, SETBP1, AIFM3 developed based on ITGB1, this accurately patient immunological status. In conclusion, study shows restrain migratory invasive capabilities accelerate apoptosis, role might be PI3K‐AKT, highlighting potential a diagnostic marker therapeutic target

Язык: Английский

Процитировано

17

CircRNAs: Pivotal modulators of TGF-β signalling in cancer pathogenesis DOI Creative Commons
Asif Ahmad Bhat, Gaurav Gupta, Rajiv Dahiya

и другие.

Non-coding RNA Research, Год журнала: 2024, Номер 9(2), С. 277 - 287

Опубликована: Янв. 26, 2024

The intricate molecular landscape of cancer pathogenesis continues to captivate researchers worldwide, with Circular RNAs (circRNAs) emerging as pivotal players in the dynamic regulation biological functions. study investigates elusive link between circRNAs and Transforming Growth Factor-β (TGF-β) signalling pathway, exploring their collective influence on progression metastasis. Our comprehensive investigation begins by profiling circRNA expression patterns diverse types, revealing a repertoire intricately linked TGF-β pathway. Through integrated bioinformatics analyses functional experiments, we elucidate specific circRNA-mRNA interactions that modulate signalling, unveiling regulatory controls governing this crucial Furthermore, provide compelling evidence impact circRNA-mediated modulation key cellular processes, including epithelial-mesenchymal transition (EMT), migration, cell proliferation. In addition mechanistic roles, have shown promise diagnostic prognostic biomarkers, well potential targets for therapy. Their ability critical pathways, such axis, underscores significance biology clinical applications. interplay is dissected, uncovering novel circuits contribute complexity biology. This review unravels previously unexplored dimension carcinogenesis, emphasizing role shaping landscape.

Язык: Английский

Процитировано

16

Non-invasive diagnosis for urothelial carcinoma using a dual-target DNA methylation biomarker panel DOI Creative Commons
Jingyao Hou,

Yaqian Niu,

Jiamin Yan

и другие.

Clinica Chimica Acta, Год журнала: 2025, Номер unknown, С. 120164 - 120164

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

1

Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder DOI

Lucas Motta Martinez,

Letícia Carina Ribeiro, Roberto Guidi

и другие.

Current Oncology Reports, Год журнала: 2025, Номер unknown

Опубликована: Фев. 12, 2025

Язык: Английский

Процитировано

1

Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials DOI Creative Commons

Daniela F. Ward Grados,

Hamed Ahmadi, Thomas S. Griffith

и другие.

Immunological Investigations, Год журнала: 2022, Номер 51(8), С. 2226 - 2251

Опубликована: Сен. 9, 2022

For nearly 50 years, immunotherapy has been used in patients with bladder cancer the form of Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which is still first-line therapy for non-muscle invasive disease. However, remarkable results obtained checkpoint inhibitor drugs, including Pembrolizumab and Atezolizumab, have fueled quest to optimize these other forms both as well advanced cancer. In this review we summarize current state rapidly evolving field highlighting novel approaches ongoing trials exciting area research.

Язык: Английский

Процитировано

32

Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer DOI Creative Commons

Qiao Xiong,

Dechao Feng, Ziwei Wang

и другие.

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Март 22, 2022

Fatty acid metabolism (FAM) genes are potentially useful for predicting prognosis and immunotherapy response in bladder cancer (BC). To examine this, we constructed a prognostic model identified key FAM BC. Using transcriptional expression profiles clinical data of BC patients from public datasets Changhai (CH) hospital, built validated risk-score based on 13 genes. Differential gene fatty synthase (FASN) as central to FASN was differentially expressed between normal tumor tissue, related survival. In the CH dataset, independently predicted muscle-invasive differential significantly immune-cell infiltration with low responded better immune checkpoint inhibitor (ICI) treatment. SREBF1 most significant transcription factor FASN. Competing endogenous RNA network analysis suggested that lncRNA AC107027.3 may upregulate by competitively binding miR-27A-3p, thereby regulating Dasatinib temsirolimus potential FASN-targeting drugs. Our efficiently is metabolism, indicator regulator ICI

Язык: Английский

Процитировано

31

Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion DOI Creative Commons
Andrey Soares, María T. Bourlon, Alvin Wong

и другие.

Clinical Genitourinary Cancer, Год журнала: 2024, Номер 22(2), С. 467 - 475

Опубликована: Янв. 4, 2024

Urothelial carcinoma (UC) is the 10

Язык: Английский

Процитировано

7

The value of urinary exosomal microRNA‐21 in the early diagnosis and prognosis of bladder cancer DOI Creative Commons

Fu‐Kan Yang,

Chao Tian,

Lin‐Xiong Zhou

и другие.

The Kaohsiung Journal of Medical Sciences, Год журнала: 2024, Номер 40(7), С. 660 - 670

Опубликована: Май 27, 2024

Bladder cancer (BC) poses high morbidity and mortality, with urinary exosomal microRNA (miR)-21 showing potential value in its diagnosis prognosis, we probed specific role. We prospectively selected 116 BC patients healthy volunteers as the control groups, respectively. miR-146a-5p, miR-93-5p, miR-663b, miR-21, miR-4454 relative expression levels were assessed. The correlations between clinical indexes prognostic of diagnostic five candidate miRNAs, urine cytology, miRNA joint panel for miR-4454, cytology Ta-T1 T2-T4 stage analyzed. Urinary highly expressed patients. combined panel, had certain BC, co-diagnostic highest value. Collectively, miR-21 was closely related to Tumor-Node-Metastasis staging grading predictive poor providing an effective indicator occurrence, development, assessment BC.

Язык: Английский

Процитировано

7

Current advances in the application of nanomedicine in bladder cancer DOI Open Access
Chi Zhang, Jiang Zhao, Weihao Wang

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2022, Номер 157, С. 114062 - 114062

Опубликована: Дек. 2, 2022

Bladder cancer is the most common malignant tumor of urinary system, however there are several shortcomings in current diagnostic and therapeutic measures. In terms diagnosis, tools currently available not sufficiently sensitive specific, imaging poor, leading to misdiagnosis missed diagnoses, which can delay treatment. treatment, treatment options include surgery, chemotherapy, immunotherapy, gene therapy, other emerging treatments, as well combination therapies. However, main reasons for poor efficacy side effects during lack specificity targeting, improper dose control drugs photosensitizers, damage normal cells while attacking cells, difficulty delivering siRNA cells. Nanomedicine an approach. Among many nanotechnologies applied medical field, nanocarrier-assisted drug delivery systems have attracted extensive research interest due their great translational value. Well-designed nanoparticles deliver agents or specific cell types within target organs through active targeting passive (enhanced permeability retention), allows imaging, cancer. This paper reviews advances application various nanocarriers advantages drawbacks, with a focus on use diagnosis bladder

Язык: Английский

Процитировано

23